Safety and Efficacy of G-Pen Compared to Lilly Glucagon for Hypoglycemia Rescue in Adult Type 1 Diabetics
Phase 3
Completed
- Conditions
- Diabetes Mellitus, Type 1Hypoglycemia
- Interventions
- Drug: G-Pen (glucagon injection)Drug: Lilly Glucagon (glucagon injection [rDNA origin])
- First Posted Date
- 2016-01-14
- Last Posted Date
- 2018-10-30
- Lead Sponsor
- Xeris Pharmaceuticals
- Target Recruit Count
- 80
- Registration Number
- NCT02656069
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸ProSciento, Inc., Chula Vista, California, United States
🇺🇸AMCR Institute, Escondido, California, United States
G-Penâ„¢ for Hypoglycemia Rescue in T1D Patients
- First Posted Date
- 2015-04-22
- Last Posted Date
- 2017-07-07
- Lead Sponsor
- Xeris Pharmaceuticals
- Target Recruit Count
- 7
- Registration Number
- NCT02423980
- Locations
- 🇺🇸
Diablo Clinical Research, Inc., Walnut Creek, California, United States
Safety and Efficacy Study of Mini-Dose Glucagon (G-Pen Mini) in Patients With Type 1 Diabetes
Phase 2
Completed
- Conditions
- Hypoglycemia
- Interventions
- Drug: G-Pen Miniâ„¢ (glucagon injection)
- First Posted Date
- 2014-03-07
- Last Posted Date
- 2018-04-05
- Lead Sponsor
- Xeris Pharmaceuticals
- Target Recruit Count
- 13
- Registration Number
- NCT02081014
- Locations
- 🇺🇸
Baylor College of Medicine, Children's Nutritional Research Center, Texas Children's Hospital, Houston, Texas, United States
PK/PD Study With G-Pump (Glucagon Infusion) in T1DM Patients
Phase 2
Completed
- Conditions
- Hypoglycemia
- Interventions
- Drug: Novo Nordisk GlucaGen®Drug: G-Pump™ (glucagon infusion)
- First Posted Date
- 2014-03-07
- Last Posted Date
- 2018-04-06
- Lead Sponsor
- Xeris Pharmaceuticals
- Target Recruit Count
- 19
- Registration Number
- NCT02081001
- Locations
- 🇺🇸
Oregon Health & Science University, Portland, Oregon, United States
Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of G-Pen(TM) (Glucagon Injection) to Treat Severe Hypoglycemia
Phase 2
Completed
- Conditions
- Hypoglycemia
- Interventions
- Drug: G-Pen(TM) 1 mgDrug: Lilly Glucagon(TM) 1 mgDrug: G-Pen(TM) 0.5 mg
- First Posted Date
- 2013-10-30
- Last Posted Date
- 2016-02-03
- Lead Sponsor
- Xeris Pharmaceuticals
- Target Recruit Count
- 30
- Registration Number
- NCT01972152
- Locations
- 🇺🇸
Texas Diabetes Institute, University Health System, San Antonio, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath